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Abstract
Background: Tetrandrine inhibits tumor cell proliferation and demonstrates chemoprevention in
cancer models. Speculation on the association between its effects on K+ and Ca2+ channels and
cancer chemoprevention has been made. Thapsigargin also affects K+ and Ca2+ conductance.
Thapsigargin, however, is a weak tumor promoter in the two-stage model of mouse skin
carcinogenesis, yet it can induce apoptosis in androgen-independent prostatic cancer cells. I have
postulated that arachidonic acid release from cells in culture is associated with cancer
chemoprevention. The effects of tetrandrine and thapsigargin on arachidonic acid release from
human colon carcinoma and rat liver cells and prostacyclin production by rat liver cells are
compared in the current studies.
Results:  Tetrandrine and thapsigargin stimulate arachidonic acid release from human colon
carcinoma and rat liver cells and prostacyclin production in rat liver cells. The stimulation by
tetrandrine is not affected by incubation with actinomycin D, 100 mM KCl, the [Ca2+]i chelator, 1,2-
bis (o-amino-5-fluorophenoxy) ethane-N,N,N',N',-tetraacetic acid tetraacetoxymethylester
(BAPTA/AM) or in the absence of extracellular Ca2+. In contrast, stimulation by thapsigargin is
inhibited by incubation with actinomycin D, 1 0 0  m M  K C l ,  B A P T A / A M  o r  i n  t h e  a b s e n c e  o f
extracellular Ca2+.
Conclusion: Both tetrandrine and thapsigargin stimulate arachidonic acid release, but based on
the different results obtained in the presence of actinomycin D, the [Ca2+]i chelator, 100 mM KCl
and in the absence of extracellular Ca2+, the mechanisms leading to this release and pathways
leading to apoptosis and/or cancer chemoprevention may be different. Stimulations by tetrandrine
may be mediated by activation of a secretory phospholipase A2, whereas thapsigargin's stimulations
may be mediated by the cytoplasmic Ca2+-dependent phospholipase A2.
Background
Tetrandrine (TET), a bisbenzylisoquinoline (Fig. 1a), iso-
lated from the root of the plant Stephania tetrandra has a
number of potential medicinal properties. These include
blockage of voltage-gated Ca2+ channels [1], large-con-
ductance Ca2+ activated K+ (BK) channels, and intracellu-
lar Ca2+ pumps [1-6]. TET also has anti-inflammatory
[2,7] and anti-cancer activities [8,9]. TET stimulates
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prostaglandin (PG)E2 production by macrophages [10],
probably after first releasing the substrate, arachidonic
acid (AA) by altering phospholipase (Plase) activities. TET
also induces apoptosis in many cell types including
human leukemic (U937), human lung carcinoma (A549),
human hepatoblastoma (HEPG2), neuro 2a mouse neu-
roblastoma and rat glioma cells (C-6) [11-14].
Thapsigargin (THAP), a hexaoxygenated tetracycle ses-
quiterpine lactone, (Fig. 1b) isolated from the plant Thap-
sia garganica, also has a number of potential medicinal
applications [15]. However, THAP is classified as a weak
tumor promoter as measured in the two-stage model of
mouse skin carcinogenesis [16]. Nevertheless, THAP [17]
and its enzymatically modified analog [18] have been
proposed as targeted therapy for prostate cancer. THAP,
like TET, blocks intracellular calcium pumps resulting in
increased cytoplasmic Ca2+, ([Ca2+]i) [reviewed in 15]. It
also affects ion channels. THAP induces a Ca2+-dependent
release of AA from [3H]-AA labelled macrophages and
stimulates AA metabolism in the rat peritoneal macro-
phages [19]. THAP induces apoptosis in many cells
including human neuroblastoma, colon cancer and pros-
tate cancer cells and thymocytes [17,20-22].
Based on the stimulation of AA release by known cancer
chemopreventative agents, I have proposed that AA
release by cells is associated with cancer chemoprevention
[23-27], possibly, but not necessarily, by activating a
secreted tumor suppressor phospholipase A2  (PLA2)
[28,29]. In this report, evidence is presented that TET, a
potential cancer chemopreventive compound, and THAP,
a weak tumor promoter that also possesses potential can-
cer preventative properties for androgen-independent
prostate cancer, both stimulate AA release from human
colon carcinoma and rat liver cells. Both compounds also
stimulate prostacyclin (PGI2) production in rat liver cells.
The release of AA and AA metabolites appears to be initi-
ated by different mechanisms.
Results
TET and THAP release AA from human colon carcinoma
(HT-29) cells and rat liver (C-9) cells in a concentration-
dependent fashion (Fig. 2a – 2d respectively). As little as
0.1 to 0.3 µM THAP stimulates AA release. With both HT-
29 and C-9 cells, THAP is about 10 to 30 times more
potent than TET. Characterizations of these effects are
shown in Table 1. Pre-incubation with actinomycin D par-
tially inhibits stimulation by THAP but does not affect
stimulation by TET. TET's stimulation of AA release does
not require new mRNA synthesis, whereas THAP's stimu-
lation does. As shown below, THAP's stimulation is medi-
ated, in part, by the Ca2+-dependent PLA2 an induced
enzyme. The absence of extracellular Ca2+ partially inhib-
its THAP's stimulations but does not affect the AA release
stimulated by TET. Depolarization of the cells with 100
mM KCl does not affect TET's stimulations, but does par-
tially inhibit release of AA stimulated by THAP. Pre-incu-
bation with the L-TYPE Ca2+ channel blocker, diltiazem,
has no effect on the actions of either TET or THAP in HT-
29 or C-9 cells.
The role of [Ca2+]i in these stimulations is striking. While
pre-incubation with the [Ca2+]i chelator, BAPTA/AM (16
µg/ml), does not affect TET's stimulation of AA release
from HT-29 cells, such treatment does inhibit THAP's
stimulation of AA release from the HT-29 cells (Fig. 3,
Table 1). Thus, a role for intracellular Ca2+ pumps is
strongly suggested only for the action of THAP. Ohuchi et
al [19] had shown that [Ca2+]i increased within 2 min after
treatment with THAP as measured by fluorescence
changes in Quin 2 loaded peritoneal cells. A similar rise in
[Ca2+]i has been measured after administration of THAP
to thymocytes, rat liver microsomes [30] and in macro-
phages, astrocytoma cells, fibroblasts and human tumor
lymphocytes [31]. The findings that the increased AA
release is stimulated 5 minutes after incubation of HT-29
a): Tetrandrine (TET), isolated from the plant Stephania  tetrandra (Structure reproduced with permission from G.  Wang [9]) and b): Thapsigargin(THAP), isolated from the  plant Thapsia garganica (Structure reproduced with permis- sion from S. B. Christensen [15]) Figure 1
a): Tetrandrine (TET), isolated from the plant Stephania 
tetrandra (Structure reproduced with permission from G. 
Wang [9]) and b): Thapsigargin(THAP), isolated from the 
plant Thapsia garganica (Structure reproduced with permis-
sion from S. B. Christensen [15]).BMC Pharmacology 2005, 5:12 http://www.biomedcentral.com/1471-2210/5/12
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and C-9 cells with THAP is consistent with a role for
increased [Ca2+]i in the activities of THAP (Fig 4a, 4b).
While both cells express COX activity [32,33], only the
major product of COX activity (PGI2) can be quantita-
tively estimated at the low cell densities used in these
studies. Both TET and THAP stimulate PGI2 (measured as
6-keto PGF1α ) production in these C-9 cells (Fig. 5a, 5b).
As with AA release, THAP is at least 10-times more potent
at stimulating PGI2 production than TET.
The likely role of [Ca2+]i in the stimulation of PGI2 pro-
duction by THAP is shown in Fig. 6. Chelation of the
increased [Ca2+]i with BAPTA/AM completely inhibits the
stimulation by THAP but has no effect on the stimulation
with TET.
Discussion
It has been proposed that the cancer chemopreventative
properties attributed to TET reside in its ability to effect
ion channels which leads to inhibition of cell prolifera-
tion and apoptosis [9]. Retinoic acids, tamoxifen, PPAR-
agonists, (e.g GW-7845), some non-steroidal anti-inflam-
matory drugs, vitamin D3, anti-oxidants, (e.g resveratrol
and caffeic acid phenylester) and statins all release AA
from cells in culture [23-26]. All have been shown to have
cancer preventative properties. Results of studies on corre-
lation, if any, of AA release and cancer chemoprevention
by TET or THAP have not been published. For the purpose
of this study, however, I have postulated that the cancer
chemopreventive properties of the test agent are causally
related to the capacity of that ligand to release AA. I have
also suggested that most, if not all, of these agents at µM
concentrations, may be intercalating into the cell mem-
brane and releasing AA as a result of activated PLAse activ-
ity [25,26].
The mechanism of action of non-steroidal anti-inflamma-
tory drugs that leads to apoptosis and cancer chemopre-
vention also involves stimulation of AA release and is
associated with sphingomyelin to ceramide conversion
[34]. The AA release probably results in ceramide-medi-
ated apoptosis [35]. Both TET and THAP stimulate the
release of AA from human colon carcinoma and rat liver
cells. TET does prevent cancer [reviewed in 8] but THAP is
considered to be a weak tumor promotor as measured in
the two-stage model of mouse skin carcinogenesis [19].
THAP and some of its analogs, however, do induce apop-
tosis in androgen-independent prostatic cancer cells
[17,18,36]. Apoptotic effects of THAP also have been
reported in thymocytes and mouse lymphomas, including
the WRH17-2 and WHB12 cell lines [17,20-22].
Clear differences in the pathways of AA release stimulated
by TET and THAP were found in this study. TET stimulates
AA release (Fig. 2) in HT-29 and C-9 cells and PGI2 pro-
duction in C-9 cells (Fig. 5). It has been reported that TET
blocks voltage-gated Ca2+ channels [1-7] and depolarizes
the cells [8], but blockage of these channels does not affect
AA release (Table 1). Nor is the AA release stimulated by
TET blocked by pre-incubation of the cells with actinomy-
cin D, in the presence of 100 mM KCl or in the absence of
extracellular Ca2+. It is interesting to note that
cycloheximide (178 µM), did not affect TET's induced
apoptosis in human lymphoblasts (CEM-C7) [37]. TET's
stimulation of AA release is not affected by the [Ca2+]
Effect of a) TET and b) THAP on AA release from HT-29  cells Figure 2
Effect of a) TET and b) THAP on AA release from HT-29 
cells. Effect of c) TET and d) THAP on AA release from C-9 
cells. The data are representative of several experiments. 
The analyses were performed with triplicate or quadruplicate 
dishes. * = Statistically significant vs MEM/BSABMC Pharmacology 2005, 5:12 http://www.biomedcentral.com/1471-2210/5/12
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chelator, BAPTA/AM (Fig. 3). In contrast, THAP's release
of AA by HT-29 cells is blocked by BAPTA/AM (Fig. 3), is
inhibited by pre-incubation with actinomycin D, is inhib-
ited by EGTA and is inhibited when the cells are incubated
in 100 m M KCl (Table 1). That the rise in [Ca2+]i resulting
from treatment with THAP appears to be associated with
the stimulation of AA release is suggested by the relatively
early increase, after 5 minutes, of AA release (Fig. 4). Both
TET and THAP stimulate PGI2 production in the C-9 cells
(Fig. 5), but only the PGI2 production stimulated by THAP
is inhibited by BAPTA/AM (Fig 6).
The relationship between AA release and cancer chemo-
prevention by TET and THAP could be explained, in part,
by implicating the PLA2 enzymes that catalyze the release
of AA from phospholipids. The tumor suppressing sPLA2
may be only one of sixteen structurally different PLA2
enzymes [38,39]. If the tumor suppressor genes are over-
expressed or activated, at least two cancer preventative
pathways may result, one from the activity of the group
11A tumor suppressor [Reviewed in [39]] and a second
from the AA released. The proximity of the PLA2 to the AA-
esterified phospholipid after treatment of the cells is of
importance, and may depend on the location of binding
of the test agent. For example, celecoxib binds at the upper
hydrocarbon core, close to the phospholipid head groups
whereas rofeco
xib binds at the polar head groups of the membrane [40].
Celecoxib and rofecoxib differ in their release of AA [41].
TET may activate a tumor suppressing sPLA2, while THAP
induces the Ca2+-dependent cPLA2. Both would lead to AA
release.
Conclusion
Cells treated with tetrandrine and thapsigargin share sev-
eral common features including pathways that lead to
Table 1: Effects of Diltiazem (50 µg/ml), Actinomycin D (1 µg/ml), EGTA (1 mM), KCl (100 mM), and BABTA/AM (16 µg/ml) on AA 
Release from HT-29 or C-9 Cells stimulated by TET or THAP.
Some biological effects* Agent tested Action of test agent AA Release
HT-29 C-9
TET Diltiazem Blocks L-type Ca2+ 
channels
NI NI
Ion Channels Actinomycin D Inhibits RNA synthesis NI NI
Apoptosis EGTA Chelates extracellular Ca2+ NI NI
Depolarization 100 mM KCl Depolarizes NI NI
[Ca2+]I BAPTA/AM Chelates [Ca2+]i NI **
THAP Diltiazem Blocks L-type Ca2+ 
channels
NI NI
Ion Channels Actinomycin D Inhibits RNA synthesis ↓↓
Apoptosis EGTA Chelates extracellular Ca2+ ↓↓
Depolarization 100 mM KCl Depolarizes ↓↓
[Ca2+]i BAPTA/AM Chelates [Ca2+]I ↓ **
* = References in text
NI = No Inhibition (or stimulation)
↓  = Inhibition: statistically significant
** = BAPTA/AM (16 µg/ml) stimulates AA release (6.17 ± 0.088 (4)), MEM/BSA control vs (11.6 ± 0.322 (4)), BAPTA/AM (16 µg/ml). Thus, the 
effect of BAPTA/AM on C-9 cells is not recorded.
Effect of BAPTA/AM, 16 µg/ml, on AA release by a) TET and  b) THAP from HT-29 cells Figure 3
Effect of BAPTA/AM, 16 µg/ml, on AA release by a) TET and 
b) THAP from HT-29 cells. The data are representative of 
two experiments, each with similar results. The analyses 
were performed on quadruplicate dishes. * = Statistically sig-
nificant vs MEM/BSA.BMC Pharmacology 2005, 5:12 http://www.biomedcentral.com/1471-2210/5/12
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induction of apoptosis. These properties probably reflect
their interaction with cell membranes and the altered
expression of signaling processes. One reaction that does
not appear to be shared is deesterification of a phosphol-
ipid by a PLA2. Based on the effects of inhibition of mRNA
synthesis, 100 mM KCl, extracellular and especially intra-
cellular Ca 2+, thapsigargin's release is mediated, in part,
by a Ca 2+-dependent PLA2, whereas tetrandrine's stimu-
lated release is mediated by a secretory PLA2. In addition
to the altered signaling properties that accompany the
membrane intercalation, both tetrandrine and thapsi-
gargin release biologically active AA.
Methods
The rat liver (C-9 cell line) were purchased from the Amer-
ican Type Culture Collection (Manassas, VA, USA) and
the human colon carcinoma (the HT-29 cell line) was
obtained from Dr. Basil Rigas, Chief, Division of Cancer
Prevention, SUNY at Stony Brook, NY, USA. They were
maintained in Eagle's minimum essential medium
(MEM) supplemented with 10% fetal bovine serum. [3H]
AA (91.8 Ci/mmol) was obtained from NEN Life Science
Products, Inc. (Boston, MA, USA). BAPTA/AM, the [Ca2+]i
chelator, diltiazem, the L-type Ca2+  channel agonist,
tetrandrine and thapsigargin were purchased from
BIOMOL International, (Plymouth, PA, USA). All other
reagents were from Sigma Chemical Co. (St. Louis, MO,
USA) or Calbiochem, (San Diego, CA, USA).
Two days prior to experiments, the HT-29 or C-9 cells
were treated with 0.25% trypsin-EDTA and, after addition
of minimal essential media (MEM) containing 10% fetal
calf serum, the floating cells were seeded on to 35 mm cul-
ture dishes. The plating densities varied from 0.1 to 0.5 ×
105 cells/35 mm dish. The freshly seeded cultures were
Time-course of AA release from a) HT-29 and b) C-9 cells by  TET (50 µM) and THAP (2 µM) Figure 4
Time-course of AA release from a) HT-29 and b) C-9 cells by 
TET (50 µM) and THAP (2 µM). The analyses were per-
formed on duplicate dishes. After the 60 minutes incubation, 
the AA release by TET is not statistically significant. TET's 
stimulation of AA release from HT-29 cells was not done.
Effects of a) TET and b) THAP on PGI2 (6-keto-PGF1α ) pro- duction in rat liver cells (C-9) Figure 5
Effects of a) TET and b) THAP on PGI2 (6-keto-PGF1α ) pro-
duction in rat liver cells (C-9). The data are representative of 
several experiments. The analyses were performed with trip-
licate dishes. * = Statistically significant vs MEM/BSA.BMC Pharmacology 2005, 5:12 http://www.biomedcentral.com/1471-2210/5/12
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incubated for 24-h to allow for cell attachment. After
decantation of MEM containing the fetal bovine serum,
1.0 ml fresh MEM containing 10% fetal bovine serum and
[3H] AA (0.2 mCi/ml) were added and the cells incubated
for another 24-h. The cells were washed 4 times with MEM
and incubated for various periods of time with 1.0 ml of
MEM containing 1.0 mg BSA/ml (MEM/BSA) and differ-
ent concentrations of each compound. The culture fluids
were then decanted, centrifuged at 2000 × g for 10 min,
and 200 µl of the supernate counted for radioactivity. The
MEM/BSA values are the control values. Radioactivity
recovered in the washes before the incubation was
compared to input radioactivity to calculate the % radio-
activity incorporated into the cells. For experiments on the
effects of actinomycin D, the HT-29 or C-9 cells were
washed with MEM 4 times, incubated with actinomycin D
(1 µM) for 2-h, washed once and incubated again for 6-h
in the presence or absence of actinomycin D (1 µM). For
the effects of BAPTA/AM, the pre-incubation was 50
minutes. For PGI2 production, 1.0 ml of MEM supple-
mented with 10% fetal bovine serum, void of [3H] AA,
was added after the first 24-h incubation. The cells were
incubated for another 24-h, washed three times with
MEM, then incubated with the compounds in MEM/BSA
for various periods of time. The culture fluids were
decanted and analyzed for 6-keto-PGF1α , the stable hydro-
lytic product of PGI2, by radioimmunoassay [42].
The [3H] AA release is presented as a percentage of the
radioactivity incorporated by the cells. Except for the time-
course experiments, which used duplicate dishes, three to
five culture dishes were used for each experimental point.
The data are expressed as mean values ± SEM. The data
were evaluated statistically by the unpaired Student's t-test.
A P value < 0.05 was considered significant.
Acknowledgements
My thanks to Hilda B. Gjika for preparation of the manuscript and to Dr. 
Armen H. Tashjian, Jr., Department of Genetic and Complex Diseases, 
Harvard School of Public Health, for his continuing interest in these studies.
References
1. Wang G, Lemos JR: Tetrandrine: a new ligand to block voltage-
dependent Ca2+ and Ca+- activated K+ channels.  Life Sci 1995,
56:295-306.
2. Kwan CY, Achike FI: Tetrandrine and related bis-benzylisoqui-
noline alkaloids from medicinal herbs: cardiovascular effects
and mechanisms of action.  Acta Pharmacol Sin 2002,
23:1057-1068.
3. Yao WX, Jiang MX: Effects of tetrandrine on cardiovascular
electrophysiologic properties.  Acta Pharmacol Sin 2002,
23:1069-1074.
4. Hagiwara M, Adachi-Akahane S, Nagao T: High-affinity binding of
[3H]DTZ323 to the diltiazem-binding site of L-type Ca2+
channels.  Eur J Pharmacol 2003, 466:63-71.
5. Wu SN: Large-conductance Ca2+- activated K+  channels:
physiological role and pharmacology.  Curr Med Chem 2003,
10:649-661.
6. Ransom CB, Liu X, Sontheimer H: BK channels in human glioma
cells have enhanced calcium sensitivity.  Glia 2002, 38:281-291.
7. Lai JH: Immunomodulatory effects and mechanisms of plant
alkaloid tetrandrine in autoimmune diseases.  Acta Pharmacol
Sin 2002, 23:1093-1101.
8. Chen YJ: Potential role of tetrandrine in cancer therapy.  Acta
Pharmacol Sin 2002, 23:1102-1106.
9. Wang G, Lemos JR, Iadecola C: Herbal alkaloid tetrandrine:
from an ion channel blocker to inhibitor of tumor
proliferation.  Trends Pharmacol Sci 2004, 25:120-123.
10. Pang L, Hoult JR: Cytotoxicity to macrophages of tetrandrine,
an antisilicosis alkaloid, accompanied by an overproduction
of prostaglandins.  Biochem Pharmacol 1997, 53:773-782.
11. Lai YL, Chen YJ, Wu TY, Wang SY, Chang KH, Chung CH, Chen ML:
Induction of apoptosis in human leukemic U937 cells by
tetrandrine.  Anticancer Drugs 1998, 9:77-81.
12. Lee JH, Kang GH, Kim KC, Kim KM, Park DI, Choi BT, Kang HS, Lee
YT, Choi YH: Tetrandrine-induced cell cycle arrest and apop-
tosis in A549 human lung carcinoma cells.  Int J Oncol 2002,
21:1239-1244.
13. Yoo SM, Oh SH, Lee SJ, Lee BW, Ko WG, Moon CK, Lee BH: Inhi-
bition of proliferation and induction of apoptosis by tetran-
drine in HepG2 cells.  J Ethnopharmacol 2002, 81:225-229.
14. Jin Q, Kang C, Soh Y, Sohn NW, Lee J, Cho YH, Baik HH, Kang I:
Tetrandrine cytotoxicity and its dual effect on oxidative
stress-induced apoptosis through modulating cellular redox
states in Neuro 2a mouse neuroblastoma cells.  Life Sci 2002,
71:2053-2066.
15. Treiman M, Caspersen C, Christensen SB: A tool coming of age:
thapsigargin as an inhibitor of sarco-endoplasmic reticulum
Ca2+-ATPases.  Trends Pharmacol Sci 1998, 19:131-135.
16. Hakii H, Fujiki H, Suganuma M, Nakayasu M, Tahira T, Sugimura T,
Scheuer PJ, Christensen SB: Thapsigargin, a histamine secreta-
gogue, is a non-12-O-tetradecanoylphorbol-13-acetate
(TPA) type tumor promoter in two-stage mouse skin
carcinogenesis.  J Cancer Res Clin Oncol 1986, 111:177-181.
17. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of cal-
cium, pH, and cell proliferation in the programmed (apop-
totic) death of androgen-independent prostatic cancer cells
induced by thapsigargin.  Cancer Res 1994, 54:6167-6175.
18. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H,
Christensen SB, Isaacs JT: Prostate-specific antigen-activated
Effect of BAPTA/AM, 16 µg/ml on THAP's stimulated PGI2  production by rat liver cells Figure 6
Effect of BAPTA/AM, 16 µg/ml on THAP's stimulated PGI2 
production by rat liver cells. The data are representative of 
two experiments, each with similar results. * = Statistically 
significant vs THAP or BAPTA/AM. ** = Statistically signifi-
cant vs THAP.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pharmacology 2005, 5:12 http://www.biomedcentral.com/1471-2210/5/12
Page 7 of 7
(page number not for citation purposes)
thapsigargin prodrug as targeted therapy for prostate
cancer.  J Natl Cancer Inst 2003, 95:990-1000.
19. Ohuchi K, Sugawara T, Watanabe M, Hirasawa N, Tsurufuji S, Fujiki
H, Christensen SB, Sugimura T: Analysis of the stimulative effect
of thapsigargin, a non-TPA-type tumour promoter, on ara-
chidonic acid metabolism in rat peritoneal macrophages.  Br
J Pharmacol 1988, 94:917-923.
20. Jiang S, Chow SC, Nicotera P, Orrenius S: Intracellular Ca2+ sig-
nals activate apoptosis in thymocytes: studies using the Ca2+-
ATPase inhibitor thapsigargin.  Exp Cell Res 1994, 212:84-92.
21. Kitamura Y, Miyamura A, Takata K, Inden M, Tsuchiya D, Nakamura
K, Taniguchi T: Possible involvement of both endoplasmic
reticulum-and mitochondria-dependent pathways in thapsi-
gargin-induced apoptosis in human neuroblastoma SH-SY5Y
cells.  J Pharmacol Sci 2003, 92:228-36.
22. He Q, Montalbano J, Corcoran C, Jin W, Huang Y, Sheikh MS: Effect
of Bax deficiency on death receptor 5 and mitochondrial
pathways during endoplasmic reticulum calcium pool deple-
tion-induced apoptosis.  Oncogene 2003, 22:2674-2679.
23. Levine L: Tamoxifen and the raloxifene analog LY117018:
their effects on arachidonic acid release from cell in culture
and on prostaglandin I2 production by rat liver cells.  BMC
Cancer 2004.
24. Levine L: Does the release of arachidonic acid from cells play
a role in cancer chemoprevention?  FASEB J 2003, 17:800-802.
25. Levine L: Tamoxifen stimulates arachidonic acid release from
rat liver cells by an estrogen receptor-independent, non-
genomic mechanism.  BMC Cancer 2003, 3:24.
26. Levine L: Statins stimulate arachidonic acid release and pros-
taglandin I2 production in rat liver cells.  Lipids Health Dis 2003,
2:1.
27. Levine L: Proteasome inhibitors: their effects on arachidonic
acid release from cells in culture and arachidonic acid
metabolism in rat liver cells.  BMC Pharmacol 2004, 4:15.
28. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mul-
h e r k a r  R ,  D o v e  W F ,  L a n d e r  E S :  Secretory phospholipase
Pla2g2a confers resistance to intestinal tumorigenesis.  Nat
Genet 1997, 17:88-91.
29. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buch-
berg AM: The secretory phospholipase A2 gene is a candidate
for the Mom1 locus, a major modifier of ApcMin-induced
intestinal neoplasia.  Cell 1995, 81:957-966.
30. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP: Thapsi-
gargin, a tumor promoter, discharges intracellular Ca 2+
stores by specific inhibition of the endoplasmic reticulum
Ca2+-ATPase.  Proc Natl Acad Sci U S A 1990, 87:2466-2470.
31. Orrenius S, Zhivotovsky B, Nicotera P: Regulation of cell death:
the calcium-apoptosis link.  Nat Rev Mol Cell Biol 2003, 4:552-565.
32. Shiff SJ, Rigas B: The role of cyclooxygenase inhibition in the
antineoplastic effects of nonsteroidal antiinflammatory
drugs (NSAIDs).  J Exp Med 1999, 190:445-450.
33. Rigas A, Levine L: Arachidonic acid metabolism by rat liver
cells (the C-9 cell line).  J Pharmacol Exp Ther 1984, 231:230-235.
34. Chan TA, Morin PJ, Vogelstein B, Kinzler KW: Mechanisms under-
lying nonsteroidal antiinflammatory drug-mediated
apoptosis.  Proc Natl Acad Sci U S A 1998, 95:681-686.
35. Hannun YA: Functions of ceramide in coordinating cellular
responses to stress.  Science 1996, 274:1855-1859.
36. Christensen SB, Andersen A, Kromann H, Treiman M, Tombal B,
Denmeade S, Isaacs JT: Thapsigargin analogues for targeting
programmed death of androgen-independent prostate can-
cer cells.  Bioorg Med Chem 1999, 7:1273-1280.
37. Teh BS, Chen P, Lavin MF, Seow WK, Thong YH: Demonstration
of the induction of apoptosis (programmed cell death) by
tetrandrine, a novel anti-inflammatory agent.  Int J
Immunopharmacol 1991, 13:1117-1126.
38. Laye JP, Gill JH: Phospholipase A2 expression in tumours: a tar-
get for therapeutic intervention?  Drug Discov Today 2003,
8:710-716.
39. Diaz BL, Arm JP: Phospholipase A2.  Prostaglandins Leukot Essent
Fatty Acids 2003, 69:87-97.
40. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP: Sul-
fone COX-2 inhibitors increase susceptibility of human LDL
and plasma to oxidative modification: comparison to sulfon-
amide COX-2 inhibitors and NSAIDs.  Atherosclerosis 2004,
177:235-243.
41. Levine L: Stimulated release of arachidonic acid from rat liver
cells by celecoxib and indomethacin.  Prostaglandins Leukot Essent
Fatty Acids 2001, 65:31-35.
42. Levine L: Measurement of arachidonic acid metabolites by
radioimmunoassay.  In Manual of Clinical Laboratory Immunology 3rd
edition. Edited by: Rose NR, Friedman H, Fahey JL. Washington DC:
American Society for Microbiology; 1986:685-691. 